Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test the safety and efficacy of an investigational immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar high-grade squamous intraepithelial lesion (HSIL) [vulval intraepithelial neoplasia 2 or 3 (VIN 2 or VIN 3)] associated with human papilloma virus (HPV) types 16 and/or 18. VGX-3100 is being assessed as an alternative to surgery with the potential to clear the underlying HPV infection. For more information visit our study website at: www.VINresearchstudy.com


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03180684
Study type Interventional
Source Inovio Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date August 31, 2017
Completion date December 18, 2020

See also
  Status Clinical Trial Phase
Terminated NCT02540928 - AMG 319 in HPV Positive and Negative HNSCC Phase 2
Not yet recruiting NCT05727033 - Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections N/A
Completed NCT03111251 - Multi-component Interventions to Increase HPV Vaccination in a Network of Pediatric Clinics N/A
Withdrawn NCT04849377 - RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC Phase 2
Completed NCT02873741 - New Strategies to Assess Anal Cancer Risk In Women
Completed NCT01188850 - Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100 Phase 1
Completed NCT02524223 - Prevalence of HPV Transmission During Medically Assisted Procreation Procedures N/A
Recruiting NCT01197079 - Utilization of Human Papillomavirus (HPV) Vaccine Among Young Men Who Have Sex With Men (MSM) and Parents of Boys (Aged 9 to 18 Years) N/A
Recruiting NCT05539638 - The Role of Circulating Tumour DNA in Head and Neck Cancer